ATE279947T1 - Immunglobulinähnliche domäne mit erhöhten halbwertszeiten - Google Patents

Immunglobulinähnliche domäne mit erhöhten halbwertszeiten

Info

Publication number: ATE279947T1
Authority: AT; Austria
Prior art keywords: domains; antibody; increased; half lives; immunoglobulin
Prior art date: 1996-03-18

Application number

AT97907993T

Other languages

English (en)

Inventor

Elizabeth Sally Ward

Original Assignee

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-18

Filing date

1997-03-03

Publication date

2004-11-15

1997-03-03 Application filed by Univ Texas filed Critical Univ Texas

2004-11-15 Application granted granted Critical

2004-11-15 Publication of ATE279947T1 publication Critical patent/ATE279947T1/de

Links

102000016844 Immunoglobulin-like domains Human genes 0.000 title abstract 2
108050006430 Immunoglobulin-like domains Proteins 0.000 title abstract 2
102000037865 fusion proteins Human genes 0.000 abstract 2
108020001507 fusion proteins Proteins 0.000 abstract 2
238000001727 in vivo Methods 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000002703 mutagenesis Methods 0.000 abstract 1
231100000350 mutagenesis Toxicity 0.000 abstract 1
108020001580 protein domains Proteins 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT97907993T 1996-03-18 1997-03-03 Immunglobulinähnliche domäne mit erhöhten halbwertszeiten ATE279947T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1356396P	1996-03-18	1996-03-18
PCT/US1997/003321 WO1997034631A1 (en)	1996-03-18	1997-03-03	Immunoglobin-like domains with increased half lives

Publications (1)

Publication Number	Publication Date
ATE279947T1 true ATE279947T1 (de)	2004-11-15

Family

ID=21760590

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97907993T ATE279947T1 (de)	1996-03-18	1997-03-03	Immunglobulinähnliche domäne mit erhöhten halbwertszeiten

Country Status (7)

Country	Link
EP (1)	EP0904107B1 (de)
JP (1)	JP4046354B2 (de)
AT (1)	ATE279947T1 (de)
AU (1)	AU728657B2 (de)
CA (1)	CA2249195A1 (de)
DE (1)	DE69731289D1 (de)
WO (1)	WO1997034631A1 (de)

Families Citing this family (839)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6852508B1 (en)	1997-02-28	2005-02-08	Genetics Institute, Llc	Chemokine with amino-terminal modifications
US6100387A (en) *	1997-02-28	2000-08-08	Genetics Institute, Inc.	Chimeric polypeptides containing chemokine domains
PT1037927E (pt)	1997-12-08	2004-10-29	Emd Lexigen Res Ct Corp	Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
EP1105427A2 (de) *	1998-08-17	2001-06-13	Abgenix, Inc.	Herstellung von modifizierten molekülen mit mit erhöhten halbwertszeiten
HK1042114B (zh)	1998-10-23	2006-09-29	Amgen K-A, Inc.	与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US7488590B2 (en)	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
GB9824632D0 (en)	1998-11-10	1999-01-06	Celltech Therapeutics Ltd	Biological compounds
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
KR100940380B1 (ko)	1999-01-15	2010-02-02	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
GB9908263D0 (en) *	1999-04-13	1999-06-02	Binding Site The Limited	Eliciting improved immune responses
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt)	1999-08-09	2002-07-23	Lexigen Pharm Corp	Complexos citocina-anticorpo múltiplos
US7459540B1 (en)	1999-09-07	2008-12-02	Amgen Inc.	Fibroblast growth factor-like polypeptides
EP1228214A2 (de)	1999-11-12	2002-08-07	MERCK PATENT GmbH	Erythropoietinformen mit verbesserten eigenschaften
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7229619B1 (en)	2000-11-28	2007-06-12	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP5179689B2 (ja)	2000-02-11	2013-04-10	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	抗体ベース融合タンパク質の循環系内半減期の増強
AU2001257173B2 (en)	2000-04-21	2005-09-22	Amgen Inc.	Apo-ai/aii peptide derivatives
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
DE60128216T2 (de)	2000-05-12	2008-01-10	Amgen Inc., Thousand Oaks	Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
JP5390055B2 (ja)	2000-06-29	2014-01-15	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en)	2000-11-28	2004-11-16	Medimmune, Inc.	Anti-RSV antibodies
AU1994402A (en)	2000-11-28	2002-06-11	Mediummune Inc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2008201419C1 (en) *	2000-12-12	2018-01-18	Board Of Regents, The University Of Texas System	Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en)	2000-12-12	2010-02-09	Medimmune, Llc	Molecules with extended half-lives, compositions and uses thereof
JP4336498B2 (ja)	2000-12-12	2009-09-30	メディミューン，エルエルシー	延長した半減期を有する分子ならびにその組成物および用途
AU2011253690C1 (en) *	2000-12-12	2018-01-18	Board Of Regents, The University Of Texas System	Molecules with extended half-lives, compositions and uses thereof
HUP0303428A2 (hu)	2001-03-07	2004-01-28	Merck Patent Gmbh.	Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (en)	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
US7256257B2 (en)	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
KR100900166B1 (ko)	2001-05-03	2009-06-02	메르크 파텐트 게엠베하	재조합 종양 특이적 항체 및 이들의 용도
HU229910B1 (hu)	2001-05-11	2014-12-29	Amgen Inc Thousand Oaks	A TALL-1-hez kötõdõ peptidek és rokon molekulák
US7332474B2 (en)	2001-10-11	2008-02-19	Amgen Inc.	Peptides and related compounds having thrombopoietic activity
US7138370B2 (en)	2001-10-11	2006-11-21	Amgen Inc.	Specific binding agents of human angiopoietin-2
ATE542137T1 (de)	2001-12-04	2012-02-15	Merck Patent Gmbh	Immunocytokine mit modulierter selektivität
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US7662925B2 (en)	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
ATE525398T1 (de)	2002-05-10	2011-10-15	Medimmune Inc	Epha2 monoklonale antikörper und deren anwendungsverfahren
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
ES2544527T3 (es)	2002-07-31	2015-09-01	Seattle Genetics, Inc.	Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
US8187593B2 (en)	2002-08-14	2012-05-29	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en)	2002-08-14	2013-09-10	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en)	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en)	2002-08-14	2015-03-03	Macrogenics Inc.	FcγRIIB specific antibodies and methods of use thereof
MXPA05002219A (es)	2002-08-28	2005-07-05	Immunex Corp	Composiciones y metodos para tratar una enfermedad cardiovascular.
US6919426B2 (en)	2002-09-19	2005-07-19	Amgen Inc.	Peptides and related molecules that modulate nerve growth factor activity
US7365168B2 (en)	2002-10-15	2008-04-29	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN100432105C (zh)	2002-12-17	2008-11-12	默克专利有限公司	与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
EP2368578A1 (de)	2003-01-09	2011-09-28	Macrogenics, Inc.	Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en)	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
JP4685764B2 (ja) *	2003-04-10	2011-05-18	アボットバイオセラピューティクスコーポレイション	変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
KR20110094361A (ko)	2003-04-11	2011-08-23	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
US9051373B2 (en)	2003-05-02	2015-06-09	Xencor, Inc.	Optimized Fc variants
ES2333598T5 (es)	2003-05-06	2013-09-04	Biogen Idec Hemophilia Inc	Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
ATE554108T1 (de)	2003-07-25	2012-05-15	Amgen Inc	Verfahren bezüglich ldcam und crtam
CN1871259A (zh)	2003-08-22	2006-11-29	比奥根艾迪克Ma公司	具有改变的效应物功能的经改进的抗体和制备它的方法
US8101720B2 (en)	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US20070148170A1 (en)	2005-10-03	2007-06-28	Desjarlais John R	Fc Variants With Optimized Fc Receptor Binding Properties
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
EP1673395A1 (de)	2003-10-15	2006-06-28	PDL BioPharma, Inc.	Veränderungen der serum-halbwertszeiten von fc-fusionsprotein durch mutagenese der position 250, 314 und/oder 428 der schweren kette der konstanten region von ig
CA2543484C (en)	2003-10-27	2014-02-04	Amgen Inc.	Modulation of immune response to an immunogen with ctla-4 and tnfbp
EP3434275A1 (de)	2003-11-06	2019-01-30	Seattle Genetics, Inc.	Auf die verwendung von auristatin-konjugaten mit antikörpern basierter nachweis für krebszellen
KR101135244B1 (ko)	2007-11-29	2012-04-24	한미사이언스 주식회사	인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
WO2005047337A1 (en)	2003-11-13	2005-05-26	Hanmi Pharmaceutical Co., Ltd.	A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
WO2005058961A2 (en)	2003-12-12	2005-06-30	Amgen Inc.	Antibodies specific for human galanin, and uses thereof
PT1699822E (pt)	2003-12-30	2008-07-30	Merck Patent Gmbh	Proteínas de fusão de il-7
BRPI0417916A (pt)	2003-12-31	2007-04-10	Merck Patent Gmbh	proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
AU2005205533B2 (en)	2004-01-07	2012-03-22	Novartis Vaccines And Diagnostics, Inc.	M-CSF-specific monoclonal antibody and uses thereof
AU2005206277B2 (en)	2004-01-22	2011-06-23	Merck Patent Gmbh	Anti-cancer antibodies with reduced complement fixation
BRPI0507174A (pt)	2004-01-28	2008-04-01	Syntonix Pharmaceuticals Inc	proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
WO2005092925A2 (en)	2004-03-24	2005-10-06	Xencor, Inc.	Immunoglobulin variants outside the fc region
JP2007536932A (ja)	2004-05-10	2007-12-20	マクロジェニクス，インコーポレーテッド	ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
EP1761540B1 (de)	2004-05-13	2016-09-28	Icos Corporation	Chinazolinone als inhibitoren der humanen phosphatidylinosit-3-kinase delta
CN102532321B (zh)	2004-06-18	2018-10-12	Ambrx公司	新颖抗原结合多肽和其用途
CA2572765C (en)	2004-07-08	2013-05-21	Amgen Inc.	Compound having improved bioefficiency when administered in a multidose regimen
US20150010550A1 (en)	2004-07-15	2015-01-08	Xencor, Inc.	OPTIMIZED Fc VARIANTS
CZ200755A3 (cs)	2004-07-26	2007-04-11	Biogen Idec Ma Inc.	Peptidy protilátek anti-CD154
EA012464B1 (ru)	2004-08-04	2009-10-30	Эпплайд Молекьюлар Эволюшн, Инк.	Антитело против cd20 и его применение
AU2005286770A1 (en)	2004-09-21	2006-03-30	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7442778B2 (en)	2004-09-24	2008-10-28	Amgen Inc.	Modified Fc molecules
WO2006047639A2 (en)	2004-10-27	2006-05-04	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2007024249A2 (en)	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
BRPI0517837A (pt)	2004-11-12	2008-10-21	Xencor Inc	variantes fc com ligação alterada a fcrn
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
JP2008519863A (ja)	2004-11-12	2008-06-12	シアトルジェネティクスインコーポレイティッド	Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
RU2437893C2 (ru)	2004-12-09	2011-12-27	Мерк Патент Гмбх	Варианты il-7 со сниженной иммуногенностью
US20090298195A1 (en)	2005-01-05	2009-12-03	F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H.	Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
KR100754667B1 (ko)	2005-04-08	2007-09-03	한미약품 주식회사	비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9284375B2 (en)	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
ES2707152T3 (es)	2005-04-15	2019-04-02	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
US7833979B2 (en)	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
BRPI0611069A2 (pt)	2005-05-06	2010-11-09	Zymogenetics Inc	anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
ES2569917T3 (es)	2005-06-21	2016-05-13	Xoma (Us) Llc	Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
KR20080025174A (ko)	2005-06-23	2008-03-19	메디뮨 인코포레이티드	응집 및 단편화 프로파일이 최적화된 항체 제제
JP5171621B2 (ja)	2005-07-07	2013-03-27	シアトルジェネティックス，インコーポレイテッド	フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
EP2004695A2 (de)	2005-07-08	2008-12-24	Xencor, Inc.	Optimierte anti-ep-cam-antikörper
SI1912671T1 (en)	2005-07-18	2018-01-31	Seattle Genetics, Inc.	Conjugates beta-glucuronide linker-drug
WO2007016285A2 (en)	2005-07-28	2007-02-08	Novartis Ag	M-csf specific monoclonal antibody and uses thereof
HUE029465T2 (en)	2005-08-10	2017-02-28	Macrogenics Inc	Identification and engineering of antibodies with variant Fc regions and methods of using same
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
JP4860703B2 (ja)	2005-10-06	2012-01-25	ゼンコー・インコーポレイテッド	最適化された抗ｃｄ３０抗体
CA2626082C (en)	2005-10-13	2017-04-11	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
TW200732350A (en)	2005-10-21	2007-09-01	Amgen Inc	Methods for generating monovalent IgG
EP2805971A1 (de)	2005-11-28	2014-11-26	ZymoGenetics, Inc.	IL-21-Antagonisten
WO2007070948A1 (en)	2005-12-20	2007-06-28	Arana Therapeutics Limited	Anti-inflammatory dab
US9012605B2 (en)	2006-01-23	2015-04-21	Amgen Inc.	Crystalline polypeptides
CN103232540A (zh)	2006-02-01	2013-08-07	赛法隆澳大利亚控股有限公司	结构域抗体构建体
EP2010569A4 (de)	2006-03-20	2009-09-09	Xoma Technology Ltd	Für gastrin spezifische humane antikörper, materialien und methoden
CN104761637B (zh)	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
TWI395754B (zh)	2006-04-24	2013-05-11	Amgen Inc	人類化之ｃ-ｋｉｔ抗體
WO2007127936A2 (en)	2006-04-27	2007-11-08	Pikamab, Inc.	Methods and compositions for antibody therapy
CA2660592C (en)	2006-05-26	2016-07-12	Macrogenics, Inc.	Humanized fc.gamma.riib-specific antibodies and methods of use thereof
MX2008015771A (es)	2006-06-14	2009-01-27	Macrogenics Inc	Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
US7981425B2 (en)	2006-06-19	2011-07-19	Amgen Inc.	Thrombopoietic compounds
ATE555383T1 (de)	2006-06-22	2012-05-15	Novo Nordisk As	Lösliche heterodimere rezeptoren und ihre verwendung
ATE540681T1 (de)	2006-06-26	2012-01-15	Amgen Inc	Verfahren zur behandlung von atherosklerose
AU2007281876B2 (en)	2006-06-26	2013-09-05	Macrogenics, Inc.	FcgammaRIIB-specific antibodies and methods of use thereof
CA2656224C (en)	2006-06-26	2018-01-09	Macrogenics, Inc.	Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
AT503861B1 (de)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
AT503902B1 (de)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von immunglobulinen
KR20090039739A (ko)	2006-08-03	2009-04-22	아스트라제네카 아베	αＶβ６에 대해 작용하는 항체 및 그의 용도
CL2007002225A1 (es)	2006-08-03	2008-04-18	Astrazeneca Ab	Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP5638804B2 (ja)	2006-08-04	2014-12-10	アストラゼネカアクチボラグ	ＥｒｂＢ２に対する抗体
JP5406027B2 (ja)	2006-08-04	2014-02-05	ノバルティスアーゲー	ＥｐｈＢ３特異的抗体およびその使用
PL2383297T3 (pl)	2006-08-14	2013-06-28	Xencor Inc	Zoptymalizowane przeciwciała ukierunkowane na CD19
EP3018144A1 (de)	2006-08-18	2016-05-11	XOMA Technology Ltd.	Prlr-spezifischer antikörper und verwendungen davon
EA021255B1 (ru)	2006-08-28	2015-05-29	Киова Хакко Кирин Ко., Лимитед	Антагонистические моноклональные антитела человека, специфичные в отношении light человека
CN103044550A (zh)	2006-09-01	2013-04-17	津莫吉尼蒂克斯公司	Il-31单克隆抗体的可变区序列和使用方法
CA2660795C (en)	2006-09-18	2014-11-18	Xencor, Inc.	Optimized antibodies that target hm1.24
EP2064335A4 (de)	2006-10-16	2011-03-30	Medimmune Llc	Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
AR063384A1 (es)	2006-10-25	2009-01-28	Amgen Inc	Agentes terapeuticos a base de peptidos derivados de toxinas
HU0700534D0 (en)	2006-11-24	2007-10-29	Mezoegazdasagi Biotechnologiai	Transgenic animal with enhanced immune response and method for the preparation thereof
DK2099823T4 (da)	2006-12-01	2022-05-09	Seagen Inc	Målbindingsmiddelvarianter og anvendelser deraf
KR20140119831A (ko)	2006-12-07	2014-10-10	노파르티스 아게	Ｅｐｈｂ３에 대한 길항제 항체
WO2008140603A2 (en)	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP3124045A3 (de)	2006-12-20	2017-05-03	Xoma (Us) Llc	Behandlung von il-1-beta-bedingten erkrankungen
JP2008169195A (ja)	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20100209434A1 (en)	2007-03-30	2010-08-19	Medimmune, Llc	Antibody formulation
EP2164868B1 (de)	2007-05-04	2015-03-25	Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA	Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
DK2160401T3 (da)	2007-05-11	2014-10-20	Altor Bioscience Corp	Fusionsmolekyler og il-15-varianter
DK3072525T3 (en)	2007-05-14	2018-04-30	Astrazeneca Ab	PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
EP2738257A1 (de)	2007-05-22	2014-06-04	Amgen Inc.	Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
AU2008260498B2 (en)	2007-05-30	2012-11-29	Xencor, Inc.	Methods and compositions for inhibiting CD32b expressing cells
EP1997830A1 (de)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
PL3241842T3 (pl)	2007-06-26	2024-06-10	F-Star Therapeutics Limited	Prezentacja środków wiążących
US20090028857A1 (en)	2007-07-23	2009-01-29	Cell Genesys, Inc.	Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
NZ582794A (en)	2007-07-26	2012-09-28	Amgen Inc	Modified lecithin-cholesterol acyltransferase enzymes
US20090155275A1 (en)	2007-07-31	2009-06-18	Medimmune, Llc	Multispecific epitope binding proteins and uses thereof
PE20140196A1 (es)	2007-08-09	2014-03-19	Boehringer Ingelheim Int	Anticuerpos anti-cd37
PE20090993A1 (es)	2007-08-29	2009-07-08	Sanofi Aventis	Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
US8629246B2 (en)	2007-09-26	2014-01-14	Ucb Pharma S.A.	Dual specificity antibody fusions
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
EP2050764A1 (de)	2007-10-15	2009-04-22	sanofi-aventis	Neues polyvalentes bispezifisches Antikörperformat und Verwendung
AU2008345242B2 (en)	2007-10-31	2014-02-27	Xencor, Inc.	Fc variants with altered binding to FcRn
EP3103813A1 (de)	2007-12-07	2016-12-14	ZymoGenetics, Inc.	Anti-humane il-21 monoklonale antikörper
KR101603109B1 (ko)	2007-12-07	2016-03-25	지모제넥틱스, 인코포레이티드	Ｉｌ-31에 특이적인 인간화된 항체 분자
WO2009117030A2 (en)	2007-12-19	2009-09-24	Macrogenics, Inc.	Improved compositions for the prevention and treatment of smallpox
DK2391650T3 (en)	2007-12-20	2015-01-12	Xoma Us Llc	Methods of treating gout
CA2709354C (en)	2007-12-21	2014-06-17	Amgen Inc.	Anti-amyloid antibodies and uses thereof
ES2613963T3 (es)	2008-01-18	2017-05-29	Medimmune, Llc	Anticuerpos manipulados con cisteína para conjugación específica de sitio
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
EP2265283B1 (de)	2008-03-18	2014-09-03	Seattle Genetics, Inc.	Auristatin-arznei-linker-konjugate
HUE029925T2 (en)	2008-04-02	2017-04-28	Macrogenics Inc	HER2 / neu-specific antibodies and methods using them
JP5785490B2 (ja)	2008-04-02	2015-09-30	マクロジェニクス，インコーポレーテッド	Ｂｃｒ複合体特異的抗体およびその使用方法
EP2275443B1 (de)	2008-04-11	2015-12-02	Chugai Seiyaku Kabushiki Kaisha	Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
TWI593423B (zh) *	2008-04-25	2017-08-01	戴埃克斯有限公司	Ｆｃ受體結合蛋白
EP2113255A1 (de)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Zytotoxisches Immunglobulin
MX2010013333A (es)	2008-06-04	2011-04-05	Amgen Inc	Mutantes fgf21 y usos de los mismos.
AU2009262199B2 (en)	2008-06-27	2012-08-09	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
KR101442323B1 (ko)	2008-09-07	2014-09-25	글라이코넥스 인코포레이티드	항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
CN102264763B (zh)	2008-09-19	2016-04-27	米迪缪尼有限公司	定向于dll4的抗体及其用途
KR101834999B1 (ko) *	2008-10-14	2018-03-06	제넨테크, 인크.	이뮤노글로불린 변이체 및 그의 용도
JP5933975B2 (ja)	2008-11-12	2016-06-15	メディミューン，エルエルシー	抗体製剤
KR20160091440A (ko)	2008-11-13	2016-08-02	길리아드 칼리스토가 엘엘씨	혈액 종양에 대한 요법
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
US8775090B2 (en)	2008-12-12	2014-07-08	Medimmune, Llc	Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
JP2012513194A (ja)	2008-12-23	2012-06-14	アストラゼネカアクチボラグ	α５β１に向けられた標的結合剤およびその使用
WO2010087927A2 (en)	2009-02-02	2010-08-05	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP3385279B1 (de)	2009-03-20	2020-02-26	Amgen Inc.	Träger-immunglobuline und verwendungen davon
CA2756347A1 (en)	2009-03-24	2010-09-30	Gilead Calistoga Llc	Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP3009454A3 (de)	2009-04-20	2016-10-19	Oxford Bio Therapeutics Limited	Antikörper spezifisch gegen cadherin-17
SG175259A1 (en)	2009-04-20	2011-11-28	Gilead Calistoga Llc	Methods of treatment for solid tumors
SG175233A1 (en)	2009-04-22	2011-11-28	Merck Patent Gmbh	Antibody fusion proteins with modified fcrn binding sites
TWI560197B (en)	2009-05-05	2016-12-01	Amgen Inc	Fgf21 mutants and uses thereof
US20120052069A1 (en)	2009-05-05	2012-03-01	Amgen Inc	Fgf21 mutants and uses thereof
WO2010141329A1 (en)	2009-06-01	2010-12-09	Medimmune, Llc	Molecules with extended half-lives and uses thereof
MX2011013457A (es)	2009-06-15	2012-05-08	Biokine Therapeutics Ltd	Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
US20120237496A1 (en)	2009-06-19	2012-09-20	Joerg Birkenfeld	Protease variants
CA2766405A1 (en)	2009-06-22	2011-01-13	Medimmune, Llc	Engineered fc regions for site-specific conjugation
AU2010276160A1 (en)	2009-07-21	2012-02-09	Gilead Calistoga Llc	Treatment of liver disorders with PI3K inhibitors
AU2010282340B2 (en)	2009-08-13	2016-12-22	The Johns Hopkins University	Methods of modulating immune function
DK2464664T3 (da)	2009-08-13	2016-01-18	Crucell Holland Bv	Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110189183A1 (en)	2009-09-18	2011-08-04	Robert Anthony Williamson	Antibodies against candida, collections thereof and methods of use
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
WO2011038301A2 (en)	2009-09-25	2011-03-31	Xoma Technology Ltd.	Screening methods
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
AU2010303415B2 (en)	2009-10-07	2015-02-19	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2470569A1 (de)	2009-10-13	2012-07-04	Oxford Biotherapeutics Ltd.	Antikörper gegen epha10
US20120277144A1 (en)	2009-11-04	2012-11-01	Henricus Johannes Duckers	Novel compounds for modulating neovascularisation and methods of treatment using these compounds
AU2010321832B2 (en)	2009-11-20	2014-08-14	Amgen Inc.	Anti-Orai1 antigen binding proteins and uses thereof
NO2504364T3 (de)	2009-11-24	2018-01-06
UA109888C2 (uk)	2009-12-07	2015-10-26		ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
KR101312829B1 (ko)	2009-12-30	2013-09-27	한화엘앤씨 주식회사	ＨＯ-1 유전자 및 ＴＮＦＲ1-Ｆｃ 유전자를 동시에 발현하는 형질전환 돼지 및 그의 제조 방법
WO2011091078A2 (en)	2010-01-19	2011-07-28	Xencor, Inc.	Antibody fc variants with enhanced complement activity
PH12018501083A1 (en)	2010-03-04	2019-02-18	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AR080993A1 (es)	2010-04-02	2012-05-30	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
AR081066A1 (es)	2010-04-02	2012-06-06	Hanmi Holdings Co Ltd	Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR081755A1 (es)	2010-04-02	2012-10-17	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
AU2011237365B2 (en)	2010-04-09	2015-01-29	Amgen Inc.	BTNL9 proteins, nucleic acids, and antibodies and uses thereof
JP2013523184A (ja)	2010-04-15	2013-06-17	アムジエン・インコーポレーテツド	ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
CA2798432A1 (en)	2010-05-06	2011-11-10	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EA201291181A1 (ru)	2010-05-06	2013-05-30	Новартис Аг	Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
RU2604811C2 (ru)	2010-05-27	2016-12-10	Мерк Шарп Энд Домэ Корп.	Способ получения антител с улучшенными свойствами
EP2591000B1 (de)	2010-07-09	2017-05-17	Janssen Vaccines & Prevention B.V.	Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
PT3552619T (pt)	2010-07-09	2025-10-23	Bioverativ Therapeutics Inc	Polipéptidos de fator ix e métodos de uso dos mesmos
KR101382593B1 (ko)	2010-07-21	2014-04-10	한미사이언스 주식회사	신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MX339622B (es)	2010-08-02	2016-06-02	Macrogenics Inc	Diacuerpos covalentes y sus usos.
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
SG187908A1 (en)	2010-08-20	2013-03-28	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
US20130224191A1 (en)	2010-08-27	2013-08-29	Robert A. Stull	Notum protein modulators and methods of use
WO2012031273A2 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
US11053299B2 (en)	2010-09-21	2021-07-06	Immunity Bio, Inc.	Superkine
EP2619229B1 (de)	2010-09-21	2016-04-06	Altor BioScience Corporation	Lösliche, multimere il-15- fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung
EP2619226B1 (de)	2010-09-22	2018-09-12	Amgen Inc.	Träger-immunglobuline und verwendungen davon
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US9023791B2 (en)	2010-11-19	2015-05-05	Novartis Ag	Fibroblast growth factor 21 mutations
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
TWI654204B (zh)	2010-11-30	2019-03-21	Chugai Seiyaku Kabushiki Kaisha	具有鈣依存性的抗原結合能力之抗體
TWI655210B (zh)	2010-12-08	2019-04-01	艾伯維史坦森特瑞斯有限責任公司	新穎調節劑及其使用方法
CA2824279A1 (en)	2010-12-22	2012-06-28	Cephalon Australia Pty Ltd	Modified antibody with improved half-life
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
KR101276801B1 (ko)	2011-01-21	2013-06-19	한화엘앤씨 주식회사	ｓＴＮＦＲ1-Ｆｃ 유전자를 발현하는 형질전환 돼지 및 이의 용도
EP3763740A1 (de)	2011-01-26	2021-01-13	Celldex Therapeutics, Inc.	Anti-kit-antikörper und verwendungen davon
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
CA2827923C (en)	2011-02-25	2021-11-23	Chugai Seiyaku Kabushiki Kaisha	Fc.gamma.riib-specific fc antibody
US9340590B2 (en)	2011-03-16	2016-05-17	Amgen Inc.	Potent and selective inhibitors of NaV1.3 and NaV1.7
TWI719112B (zh)	2011-03-16	2021-02-21	賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
ES2692268T5 (en)	2011-03-29	2025-02-26	Roche Glycart Ag	Antibody fc variants
ES2608835T3 (es)	2011-04-13	2017-04-17	Bristol-Myers Squibb Company	Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
WO2015067913A1 (en)	2013-11-07	2015-05-14	Diagnodus Limited	Biomarkers
EA201391753A1 (ru)	2011-05-21	2014-08-29	Макродженикс, Инк.	Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
JP2014517846A (ja)	2011-05-25	2014-07-24	メルク・シャープ・アンド・ドーム・コーポレーション	改善された特性を有するＦｃ含有ポリペプチドの製造方法
UA113626C2 (xx)	2011-06-02	2017-02-27		Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PH12013502489B1 (en)	2011-06-03	2019-04-24	Xoma Technology Ltd	Antibodies specific for tgf-beta
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
UA126465C2 (uk)	2011-06-10	2022-10-12	Ханмі Сайенс Ко., Лтд.	Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
PL2721062T3 (pl)	2011-06-17	2019-05-31	Hanmi Science Co Ltd	Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie
CN103649121B (zh)	2011-06-28	2016-10-19	牛津生物疗法有限公司	针对adp-核糖基环化酶2的抗体
JP5997151B2 (ja)	2011-06-30	2016-09-28	中外製薬株式会社	ヘテロ二量化ポリペプチド
BR112014001274A2 (pt)	2011-07-18	2017-04-18	Arts Biologics As	composto de hormônio luteinizante, e, composição farmacêutica
GB201112429D0 (en)	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
CN111053918A (zh)	2011-09-05	2020-04-24	韩美科学株式会社	一种包含干扰素α-缀合物的抗癌用药物组合物
UY34346A (es)	2011-09-26	2013-04-30	Novartis Ag	Proteínas de fusión para tratar trastornos metabólicos
UY34347A (es)	2011-09-26	2013-04-30	Novartis Ag	Proteínas de función dual para tratar trastornos metabólicos
WO2013047752A1 (ja)	2011-09-30	2013-04-04	中外製薬株式会社	抗原の消失を促進する抗原結合分子
US20150050269A1 (en)	2011-09-30	2015-02-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
PT2760471T (pt)	2011-09-30	2017-03-22	Dana Farber Cancer Inst Inc	Péptidos terapêuticos
AU2012332593B2 (en)	2011-11-01	2016-11-17	Bionomics, Inc.	Anti-GPR49 antibodies
EP2773373B1 (de)	2011-11-01	2018-08-22	Bionomics, Inc.	Verfahren zur blockierung eines krebsstammzellenwachstums
EP2773664A1 (de)	2011-11-01	2014-09-10	Bionomics, Inc.	Anti-gpr49-antikörper
JP2014533247A (ja)	2011-11-01	2014-12-11	バイオノミクスインコーポレイテッド	抗体および癌を治療する方法
KR20140091031A (ko)	2011-11-04	2014-07-18	노파르티스 아게	저밀도 지단백질-관련 단백질 6 (lrp6) - 반감기 연장제 구축물
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
PL2773671T3 (pl)	2011-11-04	2022-01-24	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
US9803004B2 (en)	2011-11-11	2017-10-31	Ucb Biopharma Sprl	Albumin binding antibodies and binding fragments thereof
TWI589592B (zh)	2011-11-17	2017-07-01	輝瑞股份有限公司	胞毒性肽類以及其抗體藥物共軛體
CA3233142A1 (en)	2011-11-30	2013-06-06	Chugai Seiyaku Kabushiki Kaisha	Drug containing carrier into cell for forming immune complex
JP2015500829A (ja)	2011-12-05	2015-01-08	ノバルティスアーゲー	上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
KR102083957B1 (ko)	2011-12-05	2020-03-04	노파르티스 아게	표피 성장 인자 수용체 3 (her3)에 대한 항체
JP6320300B2 (ja)	2011-12-19	2018-05-09	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	座瘡を治療するための方法
ES2728278T3 (es)	2011-12-21	2019-10-23	Novartis Ag	Composiciones que comprenden anticuerpos dirigidos al factor P y C5
EP3539982B1 (de)	2011-12-23	2025-02-19	Pfizer Inc.	Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
KR101895047B1 (ko)	2011-12-30	2018-09-06	한미사이언스 주식회사	면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
WO2013106489A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Humanized antibodies with ultralong cdr3s
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
EP2813568B1 (de)	2012-02-09	2025-04-23	Chugai Seiyaku Kabushiki Kaisha	Modifizierte fc-antikörperregionen
WO2013125667A1 (ja)	2012-02-24	2013-08-29	中外製薬株式会社	FcγRIIBを介して抗原の消失を促進する抗原結合分子
RU2014138474A (ru)	2012-02-24	2016-04-10	СтемСентРкс, Инк.	Новые модуляторы и способы применения
EA025407B1 (ru)	2012-03-05	2016-12-30	Джилид Калистога Ллс	Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
AR090281A1 (es)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko)	2012-03-09	2016-10-11	한미사이언스 주식회사	비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
US10064951B2 (en)	2012-03-30	2018-09-04	Hanmi Science Co., Ltd.	Liquid formulation of highly concentrated long-acting human growth hormone conjugate
WO2013169693A1 (en)	2012-05-09	2013-11-14	Bristol-Myers Squibb Company	Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
JP6351572B2 (ja)	2012-05-10	2018-07-04	ザイムワークス，インコーポレイテッド	Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
GB201208370D0 (en) *	2012-05-14	2012-06-27	Ucb Pharma Sa	Antibodies
AU2013263002C1 (en)	2012-05-15	2018-05-31	Seagen Inc.	Self-stabilizing linker conjugates
MX2014014086A (es) *	2012-05-23	2015-01-26	Genentech Inc	Metodo de seleccion para agentes terapeuticos.
SG10202006507XA (en)	2012-05-30	2020-08-28	Chugai Pharmaceutical Co Ltd	Target-tissue-specific antigen-binding molecule
EP3892638A1 (de)	2012-05-30	2021-10-13	Chugai Seiyaku Kabushiki Kaisha	Antigenbindende moleküle zur beseitigung von aggregierten antigenen
US9499634B2 (en)	2012-06-25	2016-11-22	Zymeworks Inc.	Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
WO2014004549A2 (en)	2012-06-27	2014-01-03	Amgen Inc.	Anti-mesothelin binding proteins
LT3495387T (lt)	2012-07-13	2021-11-25	Roche Glycart Ag	Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
AU2013292510A1 (en)	2012-07-19	2015-02-05	Amgen Inc.	Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
AR091902A1 (es)	2012-07-25	2015-03-11	Hanmi Pharm Ind Co Ltd	Formulacion liquida de un conjugado de insulina de accion prolongada
CN104812775B (zh)	2012-07-25	2019-05-03	塞尔德克斯医疗公司	抗kit抗体及其用途
AR092862A1 (es)	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
SG11201500873XA (en)	2012-08-24	2015-04-29	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc region variant
JP2015533832A (ja)	2012-10-09	2015-11-26	アイジェニカバイオセラピューティクスインコーポレイテッド	抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
ES2656298T3 (es)	2012-11-05	2018-02-26	Pfizer Inc.	Análogos de ayustoestatina
PT2916819T (pt)	2012-11-06	2019-10-28	Hanmi Pharm Ind Co Ltd	Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina.
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
CA2890571A1 (en)	2012-11-07	2014-05-15	Kenneth G. Geles	Anti-notch3 antibodies and antibody-drug conjugates
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9914785B2 (en)	2012-11-28	2018-03-13	Zymeworks Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
WO2014089177A2 (en)	2012-12-04	2014-06-12	Massachusetts Institute Of Technology	Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2014089111A1 (en)	2012-12-05	2014-06-12	Novartis Ag	Compositions and methods for antibodies targeting epo
CN105051064A (zh)	2013-01-24	2015-11-11	葛兰素史克知识产权开发有限公司	抗TNF-α抗原结合蛋白
KR102073748B1 (ko)	2013-01-31	2020-02-05	한미약품 주식회사	재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
ES2751735T3 (es)	2013-02-12	2020-04-01	Bristol Myers Squibb Co	Métodos de replegado de proteínas a elevado pH
EP2956468B1 (de)	2013-02-12	2020-06-10	Bristol-Myers Squibb Company	Tangentialstromfiltration auf der basis von proteinrückfaltungsverfahren
WO2014129895A1 (en)	2013-02-19	2014-08-28	Stichting Vu-Vumc	Means and method for increasing the sensitivity of cancers for radiotherapy
MX2015010682A (es)	2013-02-22	2016-05-31	Stemcentrx Inc	Nuevos conjugados de anticuerpos y usos de los mismos.
AR094904A1 (es)	2013-02-26	2015-09-09	Hanmi Pharm Ind Co Ltd	Análogos de insulina y su uso
SG10201907106VA (en)	2013-02-26	2019-09-27	Hanmi Pharmaceutical Co Ltd	Novel insulin analog and use thereof
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP6374412B2 (ja)	2013-03-05	2018-08-15	ハンミファーム．カンパニーリミテッドＨａｎｍｉＰｈａｒｍ．Ｃｏ．，Ｌｔｄ．	生理活性ポリペプチド結合体の高収率生産のための改善された製造方法
BR112015021707A2 (pt)	2013-03-06	2017-12-05	Hadasit Med Res Service	uso de células de planta que expresam um inibidor de polipeptídeo tnfalfa em terapia.
CA2904035A1 (en)	2013-03-06	2014-09-12	Protalix Ltd.	Tnf alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014165277A2 (en)	2013-03-12	2014-10-09	Amgen Inc.	POTENT AND SELECTIVE INHIBITORS OF Nav1.7
JP2016514130A (ja)	2013-03-14	2016-05-19	ノバルティスアーゲー	Ｎｏｔｃｈ３に対する抗体
CN111925437A (zh)	2013-03-14	2020-11-13	宏观基因有限公司	与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
EP2970940B1 (de)	2013-03-14	2018-07-25	Translate Bio, Inc.	Therapeutische mrna-zusammensetzungen und verwendung zur behandlung von krankheiten und störungen
JP2016515524A (ja)	2013-03-15	2016-05-30	アッヴィバイオテクノロジーリミテッド	抗ｃｄ２５抗体およびそれらの使用
BR112015022119A2 (pt)	2013-03-15	2017-08-29	Abbvie Biotherapeutics Inc	Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
US20150010538A1 (en)	2013-03-15	2015-01-08	Abbvie Biotherapeutics Inc.	Anti-cd25 antibodies and their uses
US9522876B2 (en)	2013-03-15	2016-12-20	Zymeworks Inc.	Cytotoxic and anti-mitotic compounds, and methods of using the same
NZ629816A (en)	2013-03-15	2017-07-28	Dana Farber Cancer Inst Inc	Therapeutic peptides
EP3473272A1 (de)	2013-03-29	2019-04-24	Alexion Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur erhöhung der serumhalbwertzeit eines therapeutischen, gegen komplement c5 gerichteten mittels
TWI636062B (zh)	2013-04-02	2018-09-21	中外製藥股份有限公司	Fc region variant
EP2992010B1 (de)	2013-04-29	2021-03-24	F.Hoffmann-La Roche Ag	Fc-receptorbindende asymmetrische modifizierte antikörper und verwendungsverfahren
SG10201800492PA (en)	2013-04-29	2018-03-28	Hoffmann La Roche	Human fcrn-binding modified antibodies and methods of use
KR101895634B1 (ko)	2013-05-31	2018-09-05	한미약품 주식회사	변이된 힌지 영역을 포함하는 IgG4 Fc 단편
SG10201708143QA (en)	2013-06-06	2017-11-29	Pf Medicament	Anti-c10orf54 antibodies and uses thereof
WO2014200349A1 (en)	2013-06-13	2014-12-18	Fast Forward Pharmaceutical B.V.	Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
UY35620A (es)	2013-06-21	2015-01-30	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096890A1 (es)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US10640574B2 (en)	2013-07-18	2020-05-05	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementary determining regions
WO2015017146A2 (en)	2013-07-18	2015-02-05	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
BR112016001376A2 (pt)	2013-07-25	2017-10-24	Novartis Ag	bioconjugados de polipeptídeos de apelin sintéticos
US9266925B2 (en)	2013-07-25	2016-02-23	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
US20160175401A1 (en)	2013-07-31	2016-06-23	Dana-Farber Cancer Institute Inc.	Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (de)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2840091A1 (de)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
WO2015053871A2 (en)	2013-08-26	2015-04-16	MabVax Therapeutics, Inc.	NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
CA2922529A1 (en)	2013-08-28	2015-03-05	Stemcentrx, Inc.	Novel sez6 modulators and methods of use
PE20160674A1 (es)	2013-08-28	2016-07-21	Stemcentrx Inc	Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
BR112016006455A2 (pt)	2013-09-27	2017-08-01	Hanmi Pharm Ind Co Ltd	?formulação de conjugado de hormônio de crescimento humano de ação prolongada?
AU2014337555C1 (en)	2013-10-15	2021-01-28	Seagen Inc.	PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
US20160235810A1 (en)	2013-10-18	2016-08-18	Novartis Ag	Methods of treating diabetes and related disorders
BR112016010169A2 (pt)	2013-11-06	2017-12-05	Stemcentrx Inc	anticorpos anticlaudina e métodos de uso
EP4570318A3 (de)	2013-11-27	2025-10-15	Zymeworks BC Inc.	Gegen her2 gerichtete bispezifische antigenbindende konstrukte
CN106029694A (zh)	2013-12-06	2016-10-12	达纳-法伯癌症研究院公司	治疗性肽
PT3082878T (pt)	2013-12-19	2022-11-30	Seagen Inc	Ligantes de carbamato de metileno para uso com conjugados de fármacos de marcação
NZ720867A (en)	2013-12-20	2018-01-26	Gilead Calistoga Llc	Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en)	2013-12-20	2015-06-25	Gilead Calistoga Llc	Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
CA2934644C (en)	2013-12-24	2023-11-21	Argen-X N.V.	Fcrn antagonists and methods of use
ES2916722T3 (es)	2013-12-27	2022-07-05	Zymeworks Inc	Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
BR112016014969A2 (pt)	2014-01-15	2018-01-23	Hoffmann La Roche	polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
EP3835318B1 (de) *	2014-01-15	2025-10-29	F. Hoffmann-La Roche AG	Fc-regionsvarianten mit modifizierten fcrn- und protein-a-bindungsfunktionen
AU2015206890B2 (en)	2014-01-20	2019-05-23	Hanmi Pharm. Co., Ltd.	Long-acting insulin and use thereof
PL3097122T3 (pl)	2014-01-24	2020-10-19	Ngm Biopharmaceuticals, Inc.	Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
CA2937731C (en)	2014-01-27	2019-09-24	Pfizer Inc.	Bifunctional cytotoxic agents
WO2015123679A1 (en)	2014-02-17	2015-08-20	Seattle Genetics, Inc.	Hydrophilic antibody-drug conjugates
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
NZ711451A (en)	2014-03-07	2016-05-27	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
CN113491766A (zh)	2014-03-14	2021-10-12	达纳－法伯癌症研究所公司	恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
UA130573C2 (uk)	2014-03-31	2026-03-25	Ханмі Фарм. Ко., Лтд.	Спосіб покращення розчинності білка та пептиду із застосуванням зв'язування з fc-фрагментом імуноглобуліну
AU2015240599B2 (en)	2014-04-04	2020-11-19	Bionomics, Inc.	Humanized antibodies that bind LGR5
ES2913205T3 (es)	2014-05-13	2022-06-01	Bioatla Inc	Proteínas biológicas activas condicionalmente
EP3142700B1 (de)	2014-05-16	2021-03-03	Medimmune, LLC	Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
DK3148579T3 (da)	2014-05-28	2021-03-08	Agenus Inc	Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
AR100639A1 (es)	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es)	2014-05-30	2016-10-26	Hanmi Pharm Ind Co Ltd	Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR102226248B1 (ko)	2014-06-04	2021-03-12	바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드	강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
KR20150140177A (ko)	2014-06-05	2015-12-15	한미약품 주식회사	단백질 및 펩타이드의 면역원성을 감소시키는 방법
AU2015271709B2 (en)	2014-06-06	2020-11-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3155002B1 (de)	2014-06-10	2019-11-27	Amgen Inc.	Apelin polypeptides
JP6455995B2 (ja)	2014-06-13	2019-01-23	ギリアードサイエンシーズ，インコーポレイテッド	ホスファチジルイノシトール３−キナーゼ阻害剤
SG11201609706VA (en)	2014-06-23	2017-01-27	Novartis Ag	Site specific protein modifications
KR102503476B1 (ko)	2014-06-30	2023-02-24	알토 바이오사이언스 코포레이션	Il-15-베이즈드 분자 및 이의 사용 방법
SG10201805646WA (en)	2014-08-07	2018-08-30	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
EP3189152A4 (de)	2014-09-03	2018-04-04	BioAtla LLC	Entdeckung und herstellung von bedingt aktiven biologischen proteinen in denselben wirten zur herstellung eukaryontischer zellen
AR101753A1 (es)	2014-09-03	2017-01-11	Boehringer Ingelheim Int	COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
TW201617368A (zh)	2014-09-05	2016-05-16	史坦森特瑞斯公司	新穎抗ｍｆｉ２抗體及使用方法
MX2017003247A (es)	2014-09-15	2017-11-30	Amgen Inc	Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
EP3194421B1 (de)	2014-09-17	2021-11-03	Zymeworks Inc.	Cytotoxische und antimitotische verbindungen und verfahren zur verwendung davon
EP3201227A4 (de)	2014-09-29	2018-04-18	Duke University	Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PL3221346T3 (pl)	2014-11-21	2021-03-08	Bristol-Myers Squibb Company	Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
TWI711630B (zh)	2014-11-21	2020-12-01	美商必治妥美雅史谷比公司	抗ｃｄ７３抗體及其用途
GB201421901D0 (en)	2014-12-09	2015-01-21	Cambridge Entpr Ltd	A method of rational antibody design
WO2016094837A2 (en)	2014-12-11	2016-06-16	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
US20160168237A1 (en)	2014-12-12	2016-06-16	Alexion Pharmaceuticals, Inc.	Method for treating a complement mediated disorder caused by an infectious agent in a patient
NZ730607A (en)	2014-12-19	2022-07-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3789039A1 (de)	2014-12-22	2021-03-10	The Rockefeller University	Anti-mertk-antikörper und verwendungen davon
MY187045A (en)	2014-12-23	2021-08-27	Bristol Myers Squibb Co	Antibodies to tigit
CR20170293A (es)	2014-12-30	2017-11-03	Hanmi Pharm Ind Co Ltd	Derivados de glucagón con estabilidad mejorada
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
CA2973978A1 (en)	2015-01-14	2016-07-21	The Brigham And Women's Hospital, Inc.	Treatment of cancer with anti-lap monoclonal antibodies
US20180215801A1 (en)	2015-01-29	2018-08-02	Board Of Trustees Of Michigan State University	Cryptic polypeptides and uses thereof
WO2016125495A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
JP2018508504A (ja)	2015-02-17	2018-03-29	ハンミファーマシューティカルカンパニーリミテッド	持続型インスリンまたはインスリンアナログ結合体
CA2977687C (en)	2015-02-24	2024-02-13	Hwai Wen Chang	Conditionally active proteins
KR102740384B1 (ko)	2015-03-03	2024-12-06	키맵 리미티드	항체, 용도 및 방법
WO2016141111A1 (en)	2015-03-03	2016-09-09	Xoma (Us) Llc	Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016151432A1 (en)	2015-03-20	2016-09-29	Pfizer Inc.	Bifunctional cytotoxic agents containing the cti pharmacophore
EA035412B1 (ru)	2015-05-29	2020-06-10	Бристол-Майерс Сквибб Компани	Антитела к ox40 и их применение
EA201792561A1 (ru)	2015-06-05	2018-04-30	Новартис Аг	Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
UY36751A (es)	2015-06-26	2017-01-31	Novartis Ag	Anticuerpos de factor xi y métodos de uso
US10479838B2 (en)	2015-06-29	2019-11-19	Bristol-Myers Squibb Company	Antibodies to CD40 with enhanced agonist activity
TN2017000555A1 (en)	2015-06-30	2019-04-12	Hanmi Pharm Ind Co Ltd	Glucagon derivative and a composition comprising a long acting conjugate of the same
WO2017021893A1 (en)	2015-08-03	2017-02-09	Novartis Ag	Methods of treating fgf21-associated disorders
CN108289928B (zh)	2015-08-06	2024-09-17	哈佛大学校长及研究员协会	改进的微生物-结合分子和其用途
UY36870A (es)	2015-08-28	2017-03-31	Hanmi Pharm Ind Co Ltd	Análogos de insulina novedosos
EP3344656A1 (de)	2015-09-01	2018-07-11	Agenus Inc.	Anti-pd-1-antikörper und verfahren zur verwendung davon
KR20180042433A (ko)	2015-09-09	2018-04-25	노파르티스 아게	흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
US10000561B2 (en)	2015-09-09	2018-06-19	Novartis Ag	Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
CA2998174A1 (en)	2015-09-15	2017-03-23	Amgen Inc.	Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
EP3341025A4 (de)	2015-09-24	2019-05-01	Hanmi Pharm. Co., Ltd.	Proteinkomplex durch verwendung einer spezifischen stelle eines immunglobulin-fragments zur verknüpfung
EP3355920A4 (de)	2015-09-29	2019-05-15	Celgene Corporation	Pd-1-bindende proteine und verfahren zur verwendung davon
JP7628764B2 (ja)	2015-09-29	2025-02-12	アムジエン・インコーポレーテツド	Ａｓｇｒ阻害剤
CA3000697A1 (en)	2015-10-01	2017-04-06	Amgen Inc.	Treatment of bile acid disorders
CN107029242A (zh)	2015-11-03	2017-08-11	财团法人工业技术研究院	抗体药物复合物及其制造方法
CA3002573A1 (en)	2015-11-03	2017-05-11	Ambrx, Inc.	Anti-cd3 antibodies and their uses
CA3005855A1 (en)	2015-11-19	2017-05-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
ES2810755T3 (es)	2015-11-30	2021-03-09	Abbvie Inc	Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso
EP3383910A1 (de)	2015-11-30	2018-10-10	AbbVie Inc.	Anti-hulrrc15-antikörper-wirkstoff-konjugate und verfahren zu deren verwendung
SG10201912984WA (en)	2015-12-02	2020-03-30	Agenus Inc	Antibodies and methods of use thereof
US20170157215A1 (en)	2015-12-04	2017-06-08	Jomoco, Corp.	Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
AU2016362777B2 (en)	2015-12-04	2020-01-30	Novartis Ag	Antibody cytokine engrafted compositions and methods of use for immunoregulation
TWI852735B (zh)	2015-12-04	2024-08-11	美商思進公司	四級胺化妥布賴森(tubulysin)化合物之結合物
US10822408B2 (en)	2015-12-15	2020-11-03	Amgen Inc.	PACAP antibodies and uses thereof
CR20180365A (es)	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CA3008102A1 (en)	2015-12-18	2017-06-22	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
JP6712323B2 (ja)	2015-12-31	2020-06-17	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
HK1257518A1 (zh)	2016-01-11	2019-10-25	Novartis Ag	针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
EP3405492B1 (de)	2016-01-21	2020-10-21	Novartis AG	Gegen cll-1 gerichtete multispezifische moleküle
AR107483A1 (es)	2016-01-29	2018-05-02	Hanmi Pharm Ind Co Ltd	Conjugado de enzimas terapéuticas
WO2017134547A1 (en)	2016-02-01	2017-08-10	Pfizer Inc.	Tubulysin analogs and methods for their preparation
KR20180114223A (ko)	2016-03-04	2018-10-17	더 락커펠러 유니버시티	증진된 효능제 활성을 갖는 cd40에 대한 항체
CA3016187A1 (en)	2016-03-04	2017-09-08	Bristol-Myers Squibb Company	Combination therapy with anti-cd73 antibodies
JP6937773B2 (ja)	2016-03-07	2021-09-22	ハンミファーマシューティカルカンパニーリミテッド	ポリエチレングリコール誘導体及びその用途
CN108884142A (zh)	2016-03-16	2018-11-23	梅里麦克制药股份有限公司	用于癌症治疗的工程化trail
KR20180138205A (ko)	2016-03-22	2018-12-28	바이오노믹스 리미티드	항-lgr5 단클론성 항체의 투여
KR102626498B1 (ko)	2016-03-25	2024-01-19	씨젠 인크.	페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
KR102775461B1 (ko)	2016-04-01	2025-02-28	어비디티 바이오사이언시스 인크.	핵산-폴리펩타이드 조성물 및 이의 용도
WO2017176651A1 (en)	2016-04-04	2017-10-12	True North Therapeutics, Inc.	Anti-complement factor bb antibodies and uses thereof
CA3020864A1 (en)	2016-04-15	2017-10-19	Macrogenics, Inc.	Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3454864A4 (de)	2016-04-21	2021-01-13	Abbvie Stemcentrx LLC	Neuartige anti-bmpr1b-antikörper und verfahren zur verwendung
CN109071647B (zh)	2016-04-27	2022-11-22	诺华股份有限公司	抗生长分化因子15的抗体及其用途
US10918627B2 (en)	2016-05-11	2021-02-16	Massachusetts Institute Of Technology	Convergent and enantioselective total synthesis of Communesin analogs
MX389710B (es)	2016-05-27	2025-03-20	Agenus Inc	Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
WO2017205726A1 (en)	2016-05-27	2017-11-30	Altor Bioscience Corporation	Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
AU2017269839A1 (en)	2016-05-27	2018-11-22	Alexion Pharmaceuticals, Inc.	Methods for treatment of refractory generalized myasthenia gravis
PL3468997T3 (pl)	2016-06-08	2024-12-16	Xencor, Inc.	Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
CA3027651A1 (en)	2016-06-15	2017-12-21	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2017218691A1 (en)	2016-06-16	2017-12-21	The Board Of Trustees Of The Leland Stanford Junior University	Humanized and chimeric monoclonal antibodies to cd81
CN109641049B (zh)	2016-06-21	2023-07-07	特尼奥生物股份有限公司	Cd3结合抗体
SG11201811697SA (en)	2016-06-29	2019-01-30	Hanmi Pharmaceutical Co Ltd	Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP3481864A1 (de)	2016-07-08	2019-05-15	Staten Biotechnology B.V.	Anti-apoc3-antikörper und verfahren zur verwendung davon
SG11201900026TA (en)	2016-07-14	2019-01-30	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
FI3494134T3 (fi)	2016-08-02	2026-02-19	Visterra Inc	Muunneltuja polypeptidejä ja niiden käyttötapoja
EP3493853A1 (de)	2016-08-03	2019-06-12	Pfizer Inc	Heteroarylsulfonbasierte konjugationsgriffe, verfahren zu deren herstellung und deren verwendung zur synthese von antikörperarzneimittelkonjugaten
BR112019001902A2 (pt)	2016-08-05	2019-07-09	Chugai Seiyaku Kabushiki Kaisha	composição para profilaxia ou tratamento de doenças relacionadas à il-8
MX2019001302A (es)	2016-08-09	2019-06-12	Seattle Genetics Inc	Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
US10981976B2 (en)	2016-08-31	2021-04-20	University Of Rochester	Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
MY200988A (en)	2016-09-14	2024-01-27	Teneobio Inc	CD3 Binding Antibodies
WO2018053405A1 (en)	2016-09-19	2018-03-22	Celgene Corporation	Methods of treating immune disorders using pd-1 binding proteins
EP3515943A4 (de)	2016-09-19	2020-05-06	Celgene Corporation	Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
BR112019005637A2 (pt)	2016-09-23	2019-07-30	Hanmi Pharm Ind Co Ltd	análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
KR102576042B1 (ko)	2016-10-11	2023-09-07	아게누스 인코포레이티드	항-lag-3 항체 및 이의 사용 방법
CN109843334A (zh)	2016-10-18	2019-06-04	西雅图基因公司	烟酰胺腺嘌呤二核苷酸补救途径抑制剂的靶向递送
EP3529618B1 (de)	2016-10-19	2020-12-02	Alexion Pharmaceuticals, Inc.	Verfahren zur quantifizierung von ungebundenem c5 in einer probe
KR102392142B1 (ko)	2016-10-21	2022-04-28	알토 바이오사이언스 코포레이션	다량체 il-15 기반 분자
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
MA46770A (fr)	2016-11-09	2019-09-18	Agenus Inc	Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CA3043528A1 (en)	2016-11-14	2018-05-17	Amgen Inc.	Bispecific or biparatopic antigen binding proteins and uses thereof
CN110662770A (zh)	2016-11-23	2020-01-07	比奥维拉迪维治疗股份有限公司	结合凝血因子ix和凝血因子x的双特异性抗体
EP3549950A4 (de)	2016-12-05	2020-08-19	Hanmi Pharm. Co., Ltd.	Konjugat mit abgeschwächter immunreaktion
WO2018104893A1 (en)	2016-12-06	2018-06-14	Glaxosmithkline Intellectual Property Development Limited	Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
FI3551660T3 (fi)	2016-12-07	2023-12-11	Agenus Inc	Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
CN118634323A (zh)	2016-12-07	2024-09-13	艾吉纳斯公司	抗体和其使用方法
KR20180071193A (ko)	2016-12-19	2018-06-27	한미약품 주식회사	뇌 표적 지속성 단백질 결합체
KR102745676B1 (ko)	2016-12-21	2024-12-24	테네오바이오, 인코포레이티드	항-bcma 중쇄-단독 항체
BR112019012667A2 (pt)	2016-12-23	2020-02-11	Novartis Ag	Anticorpos do fator xi e métodos de uso
US20200231701A1 (en)	2016-12-23	2020-07-23	Novartis Ag	Methods of treatment with anti-factor xi/xia antibodies
CN110381980A (zh)	2017-01-06	2019-10-25	艾维迪提生物科学有限责任公司	核酸-多肽组合物以及诱导外显子跳读的方法
TW201833140A (zh)	2017-01-09	2018-09-16	美商莫瑞麥克製藥公司	抗fgfr抗體及使用方法
WO2018138591A1 (en)	2017-01-24	2018-08-02	Pfizer Inc.	Calicheamicin derivatives and antibody drug conjugates thereof
AU2018215840A1 (en)	2017-02-03	2019-08-01	Hanmi Pharm. Co., Ltd.	Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof
KR20180091773A (ko)	2017-02-07	2018-08-16	한미약품 주식회사	비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
EP3580237B1 (de)	2017-02-08	2025-05-14	Novartis AG	Fgf21-mimetische antikörper und deren verwendungen
EA201991720A1 (ru)	2017-02-17	2020-01-20	Бристол-Маерс Сквибб Компани	Антитела к альфа-синуклеину и их применения
EP3592778A4 (de)	2017-03-06	2021-01-13	Altor BioScience Corporation	Il-15-basierte fusionen zu il-12 und il-18
KR101941975B1 (ko)	2017-03-17	2019-01-25	고려대학교 산학협력단	Atpif1을 함유하는 당뇨 치료용 약학조성물
WO2018174668A2 (ko)	2017-03-23	2018-09-27	한미약품 주식회사	인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
US11730822B2 (en)	2017-03-24	2023-08-22	Seagen Inc.	Process for the preparation of glucuronide drug-linkers and intermediates thereof
US20190048055A1 (en)	2017-03-31	2019-02-14	Altor Bioscience Corporation	Alt-803 in combination with anti-cd38 antibody for cancer therapies
MA49339A (fr)	2017-04-05	2020-02-12	Novo Nordisk As	Conjugués insuline-fc à extension oligomère
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
WO2018185284A1 (en)	2017-04-07	2018-10-11	Miltenyi Biotec Gmbh	POLYPEPTIDES WITH MUTANT HUMAN IgG4
JP7297672B2 (ja)	2017-04-13	2023-06-26	アジェナスインコーポレイテッド	抗ｃｄ１３７抗体およびその使用方法
JOP20190248A1 (ar)	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
CA3059133A1 (en)	2017-04-21	2018-10-25	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
WO2018200422A1 (en)	2017-04-24	2018-11-01	Alexion Pharmaceuticals, Inc.	Antibody immune cell inhibitor fusion proteins
WO2018201087A1 (en)	2017-04-27	2018-11-01	Seattle Genetics, Inc.	Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
RS64576B1 (sr)	2017-05-01	2023-10-31	Agenus Inc	Anti-tigit antitela i postupci njihove primene
CN111094335B (zh)	2017-05-15	2022-08-23	罗切斯特大学	广泛中和的抗流感单克隆抗体及其用途
CN110662762A (zh)	2017-05-24	2020-01-07	诺华股份有限公司	抗体细胞因子移植蛋白和用于治疗癌症的方法
JOP20190271A1 (ar)	2017-05-24	2019-11-21	Novartis Ag	بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215937A1 (en)	2017-05-24	2018-11-29	Novartis Ag	Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JP2020520671A (ja)	2017-05-24	2020-07-16	ノバルティスアーゲー	抗体−サイトカイングラフト化タンパク質及び使用方法
US20200299400A1 (en)	2017-05-25	2020-09-24	Bristol-Myers Squibb Company	Antibodies comprising modified heavy constant regions
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018237006A1 (en)	2017-06-20	2018-12-27	Teneoone, Inc.	Anti-bcma heavy chain-only antibodies
IL312322B2 (en)	2017-06-20	2026-05-01	Teneobio Inc	Antibodies against BCMA containing only heavy chains
EP3650539A4 (de)	2017-07-07	2021-08-18	Hanmi Pharm. Co., Ltd.	Neues therapeutisches enzymfusionsprotein und dessen verwendung
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
BR112020001703B1 (pt)	2017-07-27	2024-01-02	Alexion Pharmaceuticals, Inc	Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
TWI817952B (zh)	2017-08-25	2023-10-11	美商戊瑞治療有限公司	Ｂ７－ｈ４抗體及其使用方法
KR20200090742A (ko)	2017-08-28	2020-07-29	알토 바이오사이언스 엘엘씨	Il-7 및 il-21에의 il-15 기반 융합
RU2020112490A (ru)	2017-09-13	2021-10-13	Тенеобио, Инк.	Антитела из тяжелых цепей, связывающиеся с эктоферментами
EP3689898B1 (de)	2017-09-28	2026-04-29	Hanmi Pharm. Co., Ltd.	Langwirkendes konjugat von glucagon-like-peptid-2 (glp-2)-derivat
KR20190036956A (ko)	2017-09-28	2019-04-05	한미약품 주식회사	지속형 단쇄 인슐린 아날로그 및 이의 결합체
JP2020535199A (ja)	2017-09-29	2020-12-03	ハンミファーマシューティカルカンパニーリミテッド	効力が向上した持続性タンパク質結合体
CN111164128A (zh)	2017-09-29	2020-05-15	韩美药品株式会社	包含作为接头的非肽基聚合物偶联的脂肪酸衍生物化合物的蛋白复合物及其制备方法
US11110180B2 (en)	2017-10-04	2021-09-07	Avidity Biosciences Inc.	Nucleic acid-polypeptide compositions and uses thereof
EP3694552A1 (de)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap-antikörper und verwendungen davon
CN111630069B (zh)	2017-10-13	2024-05-31	勃林格殷格翰国际有限公司	针对Thomsen-nouvelle(Tn)抗原的人抗体
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019081983A1 (en)	2017-10-25	2019-05-02	Novartis Ag	CD32B TARGETING ANTIBODIES AND METHODS OF USE
EP3700928A1 (de)	2017-10-26	2020-09-02	Alexion Pharmaceuticals, Inc.	Dosierung und verabreichung von anti-c5-antikörpern zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh) und atypischem hämolytisch-urämischem syndrom (ahus)
CA3080103A1 (en)	2017-10-31	2019-05-09	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
EP3710589A4 (de)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s-antikörper und verfahren zur verwendung
CN118638788A (zh)	2017-12-06	2024-09-13	艾维迪提生物科学公司	治疗肌萎缩和强直性肌营养不良的组合物和方法
MX2020005981A (es)	2017-12-08	2020-08-24	Argenx Bvba	Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
CN111601613A (zh)	2017-12-22	2020-08-28	诺华股份有限公司	用fgf21变体治疗代谢障碍的方法
WO2019126756A1 (en)	2017-12-22	2019-06-27	Teneobio, Inc.	Heavy chain antibodies binding to cd22
BR112020012346A2 (pt)	2017-12-22	2020-11-24	Hanmi Pharm. Co., Ltd.	proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma
WO2019129054A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
BR112020013086A2 (pt)	2017-12-27	2020-12-08	Teneobio, Inc.	Anticorpos específicos de heterodímero de cd3-delta/épsilon
JP7284759B2 (ja)	2017-12-27	2023-05-31	ブリストル－マイヤーズスクイブカンパニー	抗ｃｄ４０抗体およびその使用
WO2019140216A1 (en)	2018-01-12	2019-07-18	Amgen Inc.	Pac1 antibodies and uses thereof
JP7358361B2 (ja)	2018-01-12	2023-10-10	ブリストル－マイヤーズスクイブカンパニー	Ｔｉｍ３に対する抗体およびその使用
WO2019154776A1 (en)	2018-02-06	2019-08-15	F. Hoffmann-La Roche Ag	Treatment of ophthalmologic diseases
US11857565B2 (en)	2018-02-20	2024-01-02	Seagen Inc.	Hydrophobic Auristatin F compounds and conjugates thereof
BR112020016986A2 (pt)	2018-02-21	2021-03-02	Five Prime Therapeutics, Inc.	formulações de anticorpo contra b7-h4
EP3758752A4 (de) *	2018-03-01	2021-12-15	IGM Biosciences Inc.	Die igm-serum-halbwertszeit beeinflussende igm-fc- und j-kettenmutationen
CA3091801A1 (en)	2018-03-02	2019-09-06	Five Prime Therapeutics, Inc.	B7-h4 antibodies and methods of use thereof
CA3093407A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
US11168138B2 (en)	2018-03-26	2021-11-09	Altor Bioscience, Llc	Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
WO2019184909A1 (zh)	2018-03-27	2019-10-03	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
CN110305210B (zh)	2018-03-27	2023-02-28	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
US20210046189A1 (en)	2018-03-30	2021-02-18	HANMl PHARM. CO., LTD.	Long-acting protein conjugates for brain targeting, a preparation method thereof, and a composition comprising the same
AU2019248547B2 (en)	2018-04-02	2025-07-17	Bristol-Myers Squibb Company	Anti-TREM-1 antibodies and uses thereof
CN110396133B (zh)	2018-04-25	2021-07-23	免疫靶向有限公司	一种以白介素12为活性成分的融合蛋白型药物前体
EP3792276A4 (de)	2018-04-26	2022-02-16	Good T Cells, Inc.	Neuartiges fusionsprotein und pharmazeutische zusammensetzung zur vorbeugung oder behandlung von krebs damit
WO2019213384A1 (en)	2018-05-03	2019-11-07	University Of Rochester	Anti-influenza neuraminidase monoclonal antibodies and uses thereof
MA52571A (fr)	2018-05-08	2021-03-17	Amgen Inc	Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US12404320B2 (en)	2018-05-31	2025-09-02	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
AU2019277029C1 (en)	2018-06-01	2024-01-04	Novartis Ag	Binding molecules against BCMA and uses thereof
JP7577542B2 (ja)	2018-06-04	2024-11-05	アレクシオンファーマシューティカルズ，インコーポレイテッド	小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
TWI851577B (zh)	2018-06-07	2024-08-11	美商思進公司	喜樹鹼結合物
EP3802590A2 (de)	2018-06-08	2021-04-14	Argenx BVBA	Zusammensetzungen und verfahren zur behandlung von immunthrombozytopenie
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
US11692017B2 (en)	2018-06-15	2023-07-04	Amyl Therapeutics Srl	General amyloid interaction motif (GAIM)
AU2019288496B2 (en)	2018-06-22	2024-11-21	Cugene Inc.	Interleukin-2 variants and methods of uses thereof
EP3814373A1 (de)	2018-06-28	2021-05-05	Alexion Pharmaceuticals, Inc.	Verfahren zur herstellung von anti-c5 -antikörpern
IL280199B2 (en)	2018-07-20	2025-08-01	Pf Medicament	Receptor for vista
BR112020024074A2 (pt)	2018-07-20	2021-02-17	Teneobio, Inc.	anticorpos de cadeia pesada com ligação a cd19
CN112543644A (zh)	2018-07-24	2021-03-23	古德T细胞有限公司	一种预防和治疗免疫相关疾病的组合物
US20220193250A1 (en)	2018-08-02	2022-06-23	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
IL317002A (en)	2018-08-10	2025-01-01	Chugai Pharmaceutical Co Ltd	Anti-CD137 antigen binding molecule and use thereof
WO2020037120A1 (en)	2018-08-16	2020-02-20	Nantbio, Inc.	Il7-il15 txm compositions and methods
AU2019343053B2 (en)	2018-09-21	2026-04-30	Teneobio, Inc.	Methods for purifying heterodimeric, multispecific antibodies
CN110964116A (zh)	2018-09-26	2020-04-07	北京辅仁瑞辉生物医药研究院有限公司	GLP1-Fc融合蛋白及其缀合物
TW202028237A (zh)	2018-09-27	2020-08-01	美商西建公司	SIRPα結合蛋白及其使用方法
AU2019352017A1 (en)	2018-10-03	2021-05-06	Staten Biotechnology B.V.	Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
US20210338779A1 (en)	2018-10-04	2021-11-04	Hanmi Pharm. Co., Ltd	Therapeutic use of glucagon and combination including the same
US11130802B2 (en)	2018-10-10	2021-09-28	Tilos Therapeutics, Inc.	Anti-lap antibody variants
JP2022502467A (ja)	2018-10-10	2022-01-11	ノヴォノルディスクアー／エス	オリゴマー伸長インスリン−ｆｃコンジュゲートおよびそれらの医学的使用
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
TWI824043B (zh)	2018-10-25	2023-12-01	西班牙商瑪製藥股份有限公司	藥物抗體共軛物
CN112955467A (zh)	2018-10-26	2021-06-11	特尼奥生物股份有限公司	与cd38结合的重链抗体
SG11202103064YA (en)	2018-10-29	2021-05-28	Hoffmann La Roche	Antibody formulation
MX2021004994A (es)	2018-10-30	2021-06-15	Alexion Pharma Inc	Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
BR112021009111A2 (pt)	2018-11-16	2021-08-24	Bristol-Myers Squibb Company	Anticorpos anti-nkg2a e usos dos mesmos
JP2022513653A (ja)	2018-11-28	2022-02-09	ブリストル－マイヤーズスクイブカンパニー	修飾された重鎖定常領域を含む抗体
IL319265A (en)	2018-12-21	2025-04-01	Avidity Biosciences Inc	Anti-transferrin receptor antibodies and their uses
AU2019405389B2 (en)	2018-12-21	2025-06-05	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition containing insulin and glucagon
JP7596268B2 (ja)	2018-12-21	2024-12-09	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに活性を有する三重活性体と、インスリンとを含む薬学組成物
EP3914622A1 (de)	2019-01-22	2021-12-01	Bristol-Myers Squibb Company	Antikörper gegen il-7r-alpha-untereinheit und deren verwendungen
ES2978570T3 (es)	2019-02-26	2024-09-16	Inspirna Inc	Anticuerpos anti-MERTK de alta afinidad y sus usos
CR20210500A (es)	2019-04-05	2021-11-05	Teneobio Inc	Anticuerpos de cadena pesada que se unen al psma
KR102524577B1 (ko)	2019-04-22	2023-04-21	전남대학교산학협력단	플라젤린 융합 단백질 및 이의 용도
CA3137715A1 (en)	2019-04-25	2020-10-29	Avidity Biosciences, Inc.	Nucleic acid compositions and methods of multi-exon skipping
CN114127114B (zh)	2019-04-30	2025-02-25	Absci公司	癌相关抗体组合物和使用方法
CA3139809A1 (en)	2019-05-10	2020-11-19	Takeda Pharmaceutical Company Limited	Antibody drug conjugates
CN114096562B (zh)	2019-05-15	2025-02-21	中外制药株式会社	抗原结合分子、药物组合物和方法
WO2020236797A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Variant cd58 domains and uses thereof
UY38701A (es)	2019-05-21	2020-12-31	Novartis Ag	Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
JP7784898B2 (ja)	2019-05-24	2025-12-12	サノフイ	全身性硬化症を治療するための方法
SG11202112926YA (en)	2019-05-30	2021-12-30	Amgen Inc	Engineering the hinge region to drive antibody dimerization
CA3142283A1 (en)	2019-06-06	2020-12-10	Avidity Biosciences, Inc.	Nucleic acid-polypeptide compositions and uses thereof
US12006499B2 (en)	2019-06-06	2024-06-11	Avidity Biosciences, Inc.	Una amidites and uses thereof
EP3980063A1 (de)	2019-06-07	2022-04-13	Argenx BVBA	Pharmazeutische formulierungen von fcrn-inhibitoren zur subkutanen verabreichung
JP7665538B2 (ja)	2019-06-14	2025-04-21	テネオバイオ，インコーポレイテッド	Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
SG11202105435PA (en)	2019-06-28	2021-06-29	Hanmi Pharmaceutical Co Ltd	Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
US20220363770A1 (en)	2019-06-28	2022-11-17	Amgen Inc.	Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
EP3999543A1 (de)	2019-07-15	2022-05-25	Bristol-Myers Squibb Company	Anti-trem-1-antikörper und verwendungen davon
CN114144435B (zh)	2019-07-15	2024-06-25	百时美施贵宝公司	针对人trem-1的抗体及其用途
MY206625A (en)	2019-07-18	2024-12-27	Hanmi Pharmaceutical Co Ltd	Novel method for preparing long-acting drug conjugate through preparation of intermediate
WO2021010531A1 (ko)	2019-07-18	2021-01-21	한미약품 주식회사	단백질 결합체의 신규 제조 방법
EP4004050A2 (de)	2019-07-30	2022-06-01	QLSF Biotherapeutics Inc.	Multispezifische bindungsverbindung mit bindung an lfrrc15 und cd3
MX2022001882A (es)	2019-08-12	2022-05-30	Aptevo Res & Development Llc	Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
KR20220053007A (ko)	2019-08-30	2022-04-28	아게누스 인코포레이티드	항-cd96 항체 및 이의 사용 방법
EP4025253B1 (de)	2019-09-05	2024-03-20	Pharma Mar, S.A.	Arzneimittel-antikörper-konjugate
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
WO2021055865A1 (en)	2019-09-19	2021-03-25	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
WO2021067820A1 (en)	2019-10-04	2021-04-08	Seagen Inc.	Formulation of antibody-drug conjugate
KR20220079606A (ko)	2019-10-04	2022-06-13	씨젠 인크.	캄프토테신 펩티드 접합체
WO2021066600A1 (ko)	2019-10-04	2021-04-08	한미약품 주식회사	글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CA3158893A1 (en)	2019-10-24	2021-04-29	Minotaur Therapeutics, Inc.	Chimeric cytokine modified antibodies and methods of use thereof
WO2021092355A1 (en)	2019-11-08	2021-05-14	Amgen Inc.	Engineering charge pair mutations for pairing of hetero-igg molecules
CA3160438A1 (en)	2019-11-19	2021-05-27	Amgen Inc.	Novel multispecific antibody format
JP7807076B2 (ja)	2019-12-13	2026-01-27	キュージーンインコーポレイテッド	新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
CN115023441A (zh)	2019-12-18	2022-09-06	特诺福尔股份有限公司	与cd38结合的重链抗体
JP2023507323A (ja)	2019-12-20	2023-02-22	アムジエン・インコーポレーテツド	固形腫瘍の治療のためのメソセリン標的化ｃｄ４０アゴニスト多重特異性抗体コンストラクト
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
CN115052619A (zh)	2019-12-24	2022-09-13	韩美药品株式会社	包含glp-2或其缀合物的用于预防或治疗代谢性骨病的药物组合物
KR20220148804A (ko)	2020-01-08	2022-11-07	아르젠엑스 비브이	천포창 장애의 치료 방법
CA3164565A1 (en)	2020-01-13	2021-07-22	Seon Myeong Lee	Therapeutic use of long-acting conjugate of triple agonist having activities to all of glucagon/glp-1/gip receptors for lung disease
BR112022017064A2 (pt)	2020-02-25	2022-11-16	Mediboston Inc	Derivados da camptotecina e seus conjugados
WO2021188390A1 (en)	2020-03-19	2021-09-23	Avidity Biosciences, Inc.	Compositions and methods of treating facioscapulohumeral muscular dystrophy
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
MX2022011892A (es)	2020-03-26	2022-10-18	Univ Vanderbilt	Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
EP4127173A4 (de) *	2020-03-27	2024-07-17	Alnylam Pharmaceuticals, Inc.	Fc-fragment von igg-rezeptor- und transporter-irna-zusammensetzungen und verfahren zur verwendung davon
WO2021195469A1 (en)	2020-03-27	2021-09-30	Avidity Biosciences, Inc.	Compositions and methods of treating muscle dystrophy
KR20210121585A (ko)	2020-03-30	2021-10-08	한국세라믹기술원	반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
CA3170570A1 (en)	2020-04-01	2021-10-07	James J. KOBIE	Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
KR20210124071A (ko)	2020-04-03	2021-10-14	한미약품 주식회사	Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물
EP4133269A1 (de) *	2020-04-08	2023-02-15	F. Hoffmann-La Roche AG	Test mit unspezifischer freigabe für grosse moleküle
US20230272056A1 (en)	2020-04-09	2023-08-31	Merck Sharp & Dohme Llc	Affinity matured anti-lap antibodies and uses thereof
PH12022552558A1 (en)	2020-04-20	2024-04-22	Genzyme Corp	Humanized anti-complement factor bb antibodies and uses thereof
JP2023521491A (ja)	2020-04-20	2023-05-24	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体を含む高脂血症の予防又は治療用薬学的組成物及び予防又は治療方法
CA3175426A1 (en)	2020-04-21	2021-10-28	Alfonso Latorre Lozano	Drug antibody conjugates
KR20230002261A (ko)	2020-04-28	2023-01-05	더 락커펠러 유니버시티	항-sars-cov-2 중화 항체 및 이의 사용 방법
IL297601A (en)	2020-04-29	2022-12-01	Teneobio Inc	Multispecific heavy chain antibodies with modified heavy chain constant regions
WO2021222616A1 (en)	2020-04-29	2021-11-04	Teneobio, Inc.	Methods of treating multiple myeloma
WO2021222578A1 (en)	2020-04-29	2021-11-04	Teneobio, Inc.	Multispecific heavy chain antibodies with modified heavy chain constant regions
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
CA3182150A1 (en)	2020-05-17	2021-11-25	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of selecting and using the same
IL298396A (en)	2020-05-22	2023-01-01	Hanmi Pharm Ind Co Ltd	Liquid formulation of long-acting conjugate of glucagon derivative
AU2021274518A1 (en)	2020-05-22	2023-01-19	Hanmi Pharm. Co., Ltd.	Liquid preparation of long-acting conjugate of glucagon/GLP-1/GIP trigonal agonist
EP4154867A4 (de)	2020-05-22	2025-01-29	Hanmi Pharm. Co., Ltd.	Flüssige formulierung
CA3179472A1 (en)	2020-05-22	2021-11-25	Sung Hee Hong	Liquid formulation of long-acting conjugate of glp-2
CN116194478A (zh)	2020-06-24	2023-05-30	阿雷克森制药公司	皮下（sc）施用抗c5抗体治疗补体相关病症
CR20230025A (es)	2020-06-26	2023-10-05	Amgen Inc	Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas
PE20230464A1 (es)	2020-06-30	2023-03-14	Teneobio Inc	Union de anticuerpos multiespecificos a bcma
CN116096397A (zh)	2020-07-15	2023-05-09	韩美药品株式会社	胰高血糖素衍生物或其缀合物对于肝脏疾病的治疗用途
WO2022012680A1 (en)	2020-07-16	2022-01-20	Nanjing Legend Biotech Co., Ltd.	Cd20 binding molecules and uses thereof
US12171804B2 (en)	2020-07-17	2024-12-24	Spectrum Pharmaceuticals, Inc.	Methods of treating chemotherapy induced neutropenia using fixed doses of eflapegrastim
EP4183419A4 (de)	2020-07-17	2025-04-02	Hanmi Pharm. Co., Ltd.	Therapeutische verwendung einer kombination mit dreifachagonistischem konjugat mit langzeitwirkung oder dreifachagonist
EP4230216A4 (de)	2020-07-24	2025-02-19	Jiangsu Gensciences Inc.	Insulin-fc-fusionsprotein und anwendung davon
WO2022031576A1 (en)	2020-08-03	2022-02-10	Janssen Biotech, Inc.	Materials and methods for multidirectional biotransportation in virotherapeutics
IL300376A (en)	2020-08-06	2023-04-01	Bioverativ Usa Inc	Inflammatory cytokines and fatigue in subjects with complement-mediated disease
IL300257A (en)	2020-08-10	2023-03-01	Astrazeneca Uk Ltd	SARS-COV-2 antibodies for the treatment and prevention of COVID-19
IL299800A (en)	2020-08-14	2023-03-01	Hanmi Pharm Ind Co Ltd	Pharmaceutical compositions containing long-acting conjugates of a triple agonist of the GLP-1/GIP glucagon receptor
JP2023538236A (ja)	2020-08-14	2023-09-07	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
JP2023538897A (ja)	2020-08-20	2023-09-12	アムジエン・インコーポレーテツド	Ｆａｂ領域中に非標準的なジスルフィドを有する抗原結合タンパク質
US20230372448A1 (en)	2020-09-25	2023-11-23	Hanmi Pharm. Co., Ltd.	Therapeutic use of long-acting conjugate of triple agonist acting on all of glucagon, glp-1 and gip receptors against multiple sclerosis
US20230355789A1 (en)	2020-09-25	2023-11-09	Hanmi Pharm. Co., Ltd.	Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
WO2022065898A1 (ko)	2020-09-25	2022-03-31	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
US20230374162A1 (en)	2020-10-07	2023-11-23	Amgen Inc.	Rational selection of building blocks for the assembly of multispecific antibodies
US20240084014A1 (en)	2020-10-16	2024-03-14	Qlsf Biotherapeutics, Inc.	Multispecific binding compounds that bind to pd-l1
CN116528885A (zh)	2020-10-16	2023-08-01	韩美药品株式会社	包括胰高血糖素/glp-1/gip三重激动剂或其长效缀合物的用于预防或治疗血管炎的药物组合物
US20230381281A1 (en)	2020-10-16	2023-11-30	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
WO2022080986A1 (ko)	2020-10-16	2022-04-21	한미약품 주식회사	Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
WO2022080991A1 (ko)	2020-10-16	2022-04-21	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도
CN116583533A (zh)	2020-10-16	2023-08-11	韩美药品株式会社	Gip衍生物、其长效缀合物和包括其的药物组合物
KR20220050819A (ko)	2020-10-16	2022-04-25	한미약품 주식회사	Gip 유도체 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
EP4240758A1 (de)	2020-11-04	2023-09-13	The Rockefeller University	Neutralisierende anti-sars-cov-2-antikörper
EP4240491A1 (de)	2020-11-06	2023-09-13	Novartis AG	Cd19-bindende moleküle und verwendungen davon
MX2023005381A (es)	2020-11-09	2023-05-23	Takeda Pharmaceuticals Co	Conjugados de anticuerpo y farmaco.
US20240002545A1 (en)	2020-11-10	2024-01-04	Amgen Inc.	Novel linkers of multispecific antigen binding domains
MX2023005580A (es)	2020-11-13	2023-05-29	Hanmi Pharmaceutical Co Ltd	Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de enfermedades renales provocadas por o acompa?adas de la enfermedad de fabry.
US20230416714A1 (en)	2020-11-13	2023-12-28	Hanmi Pharm. Co., Ltd	Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by fabry disease
TW202233684A (zh)	2020-11-18	2022-09-01	美商泰尼歐生物公司	結合於葉酸受體α之重鏈抗體
EP4255574A1 (de)	2020-12-01	2023-10-11	Aptevo Research and Development LLC	Heterodimere psma- und cd3-bindende bispezifische antikörper
KR20230117588A (ko)	2020-12-07	2023-08-08	유씨비 바이오파마 에스알엘	다중특이적 항체 및 항체 조합
KR20220086522A (ko)	2020-12-16	2022-06-23	주식회사 굳티셀	Taci 단백질의 용도
AU2021409610A1 (en)	2020-12-24	2023-07-06	Hanmi Pharm. Co., Ltd.	Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
KR20220092442A (ko)	2020-12-24	2022-07-01	한미약품 주식회사	신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
CA3202832A1 (en)	2020-12-31	2022-07-07	Romesh R. Subramanian	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2024502832A (ja)	2020-12-31	2024-01-23	アラマーバイオサイエンシーズ，インコーポレイテッド	高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
EP4277926A1 (de)	2021-01-15	2023-11-22	The Rockefeller University	Neutralisierende anti-sars-cov-2-antikörper
KR20220110117A (ko)	2021-01-29	2022-08-05	한미약품 주식회사	Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물
US12521444B2 (en)	2021-02-25	2026-01-13	Fortvita Biologics Limited	Anti-HER2 antibody-drug conjugates and uses thereof
JP2024507540A (ja)	2021-02-25	2024-02-20	テネオバイオ，インコーポレイテッド	抗ｐｓｍａ抗体及びｃａｒ－ｔ構造
CA3211142A1 (en)	2021-02-26	2022-09-01	Teneobio, Inc.	Anti-muc1-c antibodies and car-t structures
IL305886A (en)	2021-03-18	2023-11-01	Seagen Inc	Selective release of drugs from internalized conjugates of biologically active compounds
CA3213636A1 (en)	2021-03-18	2022-09-22	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
IL304365B2 (en)	2021-03-31	2025-04-01	Hanmi Pharmaceutical Co Ltd	A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
CN117241828A (zh)	2021-03-31	2023-12-15	美国比奥维拉迪维股份有限公司	减少冷凝集素病患者的手术相关溶血
TW202304994A (zh)	2021-04-02	2023-02-01	美商泰尼歐生物公司	促效性抗ｉｌ－２ｒ抗體及使用方法
EP4314068A1 (de)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antikörper gegen gespaltenes cdcp1 und verwendungen davon
KR20230166090A (ko)	2021-04-06	2023-12-06	테네오바이오, 인코포레이티드	항-cd19 항체 및 car-t 구조체
AU2022254588A1 (en)	2021-04-09	2023-09-21	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
KR20230171952A (ko)	2021-04-16	2023-12-21	테네오바이오, 인코포레이티드	항-cd20 항체 및 car-t 구조
CA3216559A1 (en)	2021-04-20	2022-10-27	Amgen Inc.	Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
CN118251420A (zh)	2021-04-28	2024-06-25	米诺陶治疗公司	人源化嵌合牛抗体和使用方法
US20240218057A1 (en)	2021-05-06	2024-07-04	The Rockefeller University	Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
CA3218481A1 (en)	2021-06-14	2022-12-22	argenx BV	Anti-il-9 antibodies and methods of use thereof
WO2022271987A1 (en)	2021-06-23	2022-12-29	TeneoFour, Inc.	Anti-cd38 antibodies and epitopes of same
MX2023015442A (es)	2021-06-25	2024-03-12	Amgen Inc	Tratamiento de la enfermedad cardiovascular con proteínas de unión a antígeno trem-1.
KR20230004135A (ko)	2021-06-30	2023-01-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023004197A1 (en)	2021-07-23	2023-01-26	Teneoten, Inc.	Heavy chain antibodies binding to hepatitis b surface antigen
JP2024535662A (ja)	2021-09-02	2024-10-02	ディー・ジェイ・エス・アンチボディーズ・リミテッド	ポリペプチド
MX2024003266A (es)	2021-09-16	2024-04-03	Avidity Biosciences Inc	Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
EP4408468A4 (de)	2021-09-28	2025-07-02	Frontaim Biomedicines Inc	Mehrere formate molekularer komplexe
MX2024003797A (es)	2021-09-30	2024-06-19	Seagen Inc	Conjugados de anticuerpos b7-h4 y farmacos para el tratamiento del cancer.
US20230192843A1 (en)	2021-10-14	2023-06-22	Teneobio, Inc.	Mesothelin binding proteins and uses thereof
TW202342095A (zh)	2021-11-05	2023-11-01	英商阿斯特捷利康英國股份有限公司	用於治療和預防ｃｏｖｉｄ—１９之組成物
AU2022394462A1 (en)	2021-11-17	2024-05-02	AbbVie Deutschland GmbH & Co. KG	Methods for treating anemia of kidney disease
KR20230095665A (ko)	2021-12-22	2023-06-29	한미약품 주식회사	간 표적 약물 및 이의 용도
KR20230095666A (ko)	2021-12-22	2023-06-29	한미약품 주식회사	간 표적 물질 및 이의 용도
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
EP4469159A1 (de)	2022-01-27	2024-12-04	The Rockefeller University	Breit neutralisierende anti-sars-cov-2-antikörper gegen die n-terminale domäne des spike-proteins und verfahren zur verwendung davon
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
US20250197448A1 (en)	2022-03-11	2025-06-19	University Of Rochester	Cyclopeptibodies and uses thereof
IL315508A (en)	2022-03-17	2024-11-01	Seagen Inc	Camptothecin conjugates
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2023204556A1 (ko)	2022-04-18	2023-10-26	한미약품 주식회사	장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법
WO2023209568A1 (en)	2022-04-26	2023-11-02	Novartis Ag	Multispecific antibodies targeting il-13 and il-18
WO2023209177A1 (en)	2022-04-29	2023-11-02	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of using the same
TW202417039A (zh)	2022-06-15	2024-05-01	美商百歐維拉提夫美國公司	抗補體ｃ１ｓ抗體調配物
CA3258004A1 (en)	2022-06-15	2023-12-21	argenx BV	FCRN/HSA BONDING MOLECULES AND METHODS OF USE
AU2023286689A1 (en)	2022-06-24	2025-02-06	Bioverativ Usa Inc.	Methods for treating complement-mediated diseases
AU2023298184A1 (en)	2022-07-01	2025-02-13	Aarhus Universitet	Displacers of ige-fceri
EP4554969A1 (de)	2022-07-15	2025-05-21	Janssen Biotech, Inc.	Material und verfahren zur verbesserten biotechnologischen paarung antigenbindender variabler regionen
JP2025524899A (ja)	2022-07-27	2025-08-01	テネオバイオ，インコーポレイテッド	メソテリン結合タンパク質及びその使用
JP2025524986A (ja)	2022-07-27	2025-08-01	メディボストンリミテッド	オーリスタチン誘導体およびそのコンジュゲート
EP4561598A1 (de)	2022-07-29	2025-06-04	Regeneron Pharmaceuticals, Inc.	Auf transferrin-rezeptor 1 neu gerichtete viruspartikel
IL318627A (en)	2022-07-29	2025-03-01	Regeneron Pharma	Anti-TFR charge fusions and methods of using them
KR20250054842A (ko)	2022-07-29	2025-04-23	리제너론 파마슈티칼스 인코포레이티드	뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
US11773160B1 (en)	2022-08-05	2023-10-03	Anaveon AG	Immune-stimulating IL-2 fusion proteins
CN119654163A (zh)	2022-08-09	2025-03-18	魁尔斯弗生物治疗股份有限公司	与clec12a结合的抗体
CA3266599A1 (en)	2022-09-07	2024-11-07	Quantitative Biosciences, Inc.	UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
CN119947756A (zh)	2022-09-26	2025-05-06	中美华世通生物医药科技(武汉)股份有限公司	包含Fc-高级脂肪酸链的超长效平台
EP4598958A1 (de)	2022-10-05	2025-08-13	Amgen Inc.	Kombinationstherapien mit t-zell-umleitenden therapien und agonistischen anti-il-2r-antikörpern oder fragmenten davon
CN120693347A (zh)	2022-11-04	2025-09-23	瑞泽恩制药公司	钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送
WO2024107765A2 (en)	2022-11-14	2024-05-23	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024107759A2 (en)	2022-11-14	2024-05-23	Regeneron Pharmaceuticals, Inc.	Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
WO2024129756A1 (en)	2022-12-13	2024-06-20	Seagen Inc.	Site-specific engineered cysteine antibody drug conjugates
WO2024130158A1 (en)	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
KR20240102890A (ko)	2022-12-23	2024-07-03	한미약품 주식회사	Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 이식편대숙주질환의 예방 또는 치료용 약학적 조성물
WO2024136575A1 (ko)	2022-12-23	2024-06-27	한미약품 주식회사	면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제
WO2024150074A2 (en)	2023-01-13	2024-07-18	Takeda Pharmaceutical Company Limited	Coronavirus antibodies and therapeutic uses thereof
EP4669669A1 (de)	2023-02-21	2025-12-31	Teneobio, Inc.	C-kit-bindende proteine, chimäre antigenrezeptoren und verwendungen davon
KR20250158054A (ko)	2023-03-02	2025-11-05	알로이 테라퓨틱스, 인크.	항-cd22 항체 및 이의 용도
TW202502372A (zh)	2023-03-07	2025-01-16	南韓商韓美藥品股份有限公司	包含ｉｌ－２類似物或其接合物之用於預防或治療癌症之醫藥組成物
IL322698A (en)	2023-03-07	2025-10-01	Hanmi Pharmaceutical Co Ltd	Combination therapy containing interleukin 2 analogs or conjugates and immune checkpoint inhibitors for the prevention or treatment of cancer
AU2024240129A1 (en)	2023-03-17	2025-10-09	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024200854A1 (en)	2023-03-31	2024-10-03	Alk-Abelló A/S	Allergen binding antibodies suitable for treating tree pollen allergies
EP4698281A1 (de)	2023-04-18	2026-02-25	QLSF Biotherapeutics, Inc.	An ly6g6d bindende antikörper
EP4735602A2 (de)	2023-06-27	2026-05-06	Atrium Therapeutics, Inc.	Zusammensetzungen und verfahren zur verwendung eines auf prkag2 abzielenden antikörper-oligonukleotid-konjugat-abstrahs
CN121793987A (zh)	2023-06-30	2026-04-03	艾维迪提生物科学公司	使用pln靶向性抗体-寡核苷酸缀合物的组合物和方法
TW202513801A (zh)	2023-07-28	2025-04-01	美商雷傑納榮製藥公司	用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
US20250049896A1 (en)	2023-07-28	2025-02-13	Regeneron Pharmaceuticals, Inc.	Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
WO2025037108A2 (en)	2023-08-15	2025-02-20	Board Of Trustees Of The Leland Stanford Junior University	Modified thrombopoietin
WO2025046298A2 (en)	2023-09-01	2025-03-06	iTeos Belgium SA	Anti-trem2 antibodies and methods of use
WO2025054181A1 (en)	2023-09-05	2025-03-13	Seagen Inc.	Targeted degrader molecules and ligand drug conjugates thereof
WO2025059215A1 (en)	2023-09-12	2025-03-20	Aadigen, Llc	Methods and compositions for treating or preventing cancer
WO2025076389A1 (en)	2023-10-06	2025-04-10	Seagen Inc.	Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates
WO2025090774A1 (en)	2023-10-24	2025-05-01	Seagen Inc.	Chemotherapeutic compounds and methods of use
WO2025104604A1 (en)	2023-11-14	2025-05-22	Janssen Pharmaceuticals, Inc.	Anti-respiratory syncytial virus antibodies and uses thereof
WO2025128343A1 (en)	2023-12-11	2025-06-19	Just-Evotec Biologics, Inc.	Protein expression using trans-splicing and split selectable markers
WO2025133707A1 (en)	2023-12-19	2025-06-26	Vectory Therapeutics B.V.	Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en)	2023-12-20	2025-06-26	argenx BV	Fcrn/hsa-binding molecules and methods of use
WO2025149947A1 (en)	2024-01-12	2025-07-17	Seagen Inc.	Antibody-drug conjugates
WO2025155877A2 (en)	2024-01-18	2025-07-24	The Regents Of The University Of California	Antibodies binding to pad4 and uses thereof
WO2025184211A1 (en)	2024-02-27	2025-09-04	Bristol-Myers Squibb Company	Anti-ceacam5 antibody drug conjugates
US20250361320A1 (en)	2024-02-27	2025-11-27	Bristol-Myers Squibb Company	Anti-ceacam5 antibodies and uses thereof
WO2025193454A1 (en)	2024-03-01	2025-09-18	Prelude Therapeutics Incorporated	Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
US20250361297A1 (en)	2024-03-12	2025-11-27	Adaptam Therapeutics, S.L.	Anti- siglec-15 binding molecules and methods of use
WO2025217101A2 (en)	2024-04-09	2025-10-16	Amgen Inc.	Agonistic anti-il-2rbg heavy‑chain antibodies
TW202544034A (zh)	2024-05-06	2025-11-16	美商榮都醫療公司	結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
WO2026006494A1 (en)	2024-06-25	2026-01-02	Alloy Therapeutics, Inc.	Anti-cd3 antibodies and uses thereof
WO2026006492A2 (en)	2024-06-25	2026-01-02	Ypsilon Therapeutics, Inc.	Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en)	2024-06-25	2026-01-02	Alloy Therapeutics, Inc.	Anti-wt1/hla-a2 antibody and uses thereof
WO2026058155A1 (en)	2024-09-11	2026-03-19	Novartis Ag	Antibodies targeting il-31
US20260115307A1 (en)	2024-10-31	2026-04-30	Bristol-Myers Squibb Company	Anti-fucosyl-gm1 antibody drug conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3095168B2 (ja) *	1988-02-05	2000-10-03	エル．モリソン，シェリー	ドメイン‐変性不変部を有する抗体
CA2118508A1 (en) *	1992-04-24	1993-11-11	Elizabeth S. Ward	Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994004689A1 (en) *	1992-08-14	1994-03-03	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Recombinant toxin with increased half-life

1997
- 1997-03-03 AT AT97907993T patent/ATE279947T1/de not_active IP Right Cessation
- 1997-03-03 JP JP53348897A patent/JP4046354B2/ja not_active Expired - Fee Related
- 1997-03-03 EP EP97907993A patent/EP0904107B1/de not_active Expired - Lifetime
- 1997-03-03 CA CA002249195A patent/CA2249195A1/en not_active Abandoned
- 1997-03-03 DE DE69731289T patent/DE69731289D1/de not_active Expired - Lifetime
- 1997-03-03 WO PCT/US1997/003321 patent/WO1997034631A1/en not_active Ceased
- 1997-03-03 AU AU19850/97A patent/AU728657B2/en not_active Ceased

Also Published As

Publication number	Publication date
JP2000507816A (ja)	2000-06-27
JP4046354B2 (ja)	2008-02-13
AU728657B2 (en)	2001-01-18
EP0904107A1 (de)	1999-03-31
WO1997034631A1 (en)	1997-09-25
CA2249195A1 (en)	1997-09-25
DE69731289D1 (de)	2004-11-25
AU1985097A (en)	1997-10-10
EP0904107B1 (de)	2004-10-20

Legal Events

Date	Code	Title	Description
2005-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69731289D1 (de)	2004-11-25	Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1993022332A3 (en)	1994-02-17	Recombinant production of immunoglobulin-like domains in prokaryotic cells
PL415463A1 (pl)	2016-04-25	Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
EA200001023A1 (ru)	2001-06-25	Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE522610T1 (de)	2011-09-15	Menschliche, metabotrope glutamatrezeptor- subtypen (hmr6) und verwandte dns-verbindungen
KR950702635A (ko)	1995-07-29	감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
CY1112334T1 (el)	2015-12-09	Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
ES2147178T3 (es)	2000-09-01	Dominio de union a cd2 del antigeno 3 asociado con la funcion linfocitica.
ATE112687T1 (de)	1994-10-15	Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
PT96097A (pt)	1991-09-30	Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados
DK1386931T3 (da)	2006-09-04	Human neurotriminhomolog
WO2000043419A3 (en)	2001-02-15	Exocytosis pathway proteins and methods of use
DE69932644D1 (de)	2006-09-14	Menschliches Protein mit in vitro antiproliferativer Aktivität.
ATE290549T1 (de)	2005-03-15	Ing2, ein mit iaps assoziiertes zellzyklusprotein,sowie zusammensetzungen, verfahren und verwendungen
DE59914878D1 (de)	2008-11-13	Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika
WO2000055192A3 (de)	2002-04-18	Hämocyanin und dafür kodierende nukleinsäuresequenz
SE9804491D0 (sv)	1998-12-22	Novel fibronectin-binding protein
WO2000007545A3 (en)	2000-11-23	Apoptosis proteins
DE69931282D1 (de)	2006-06-14	Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
PT1241185E (pt)	2005-04-29	Acido nucleico que e amplificado em tumores humanos e materiais e metodos relacionados
ATE380864T1 (de)	2007-12-15	Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
DE69927190D1 (de)	2005-10-13	Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
ATE404585T1 (de)	2008-08-15	Menschliches synaptogyrin-ähnliches protein und dafür kodierende nukleinsäure
ATE405590T1 (de)	2008-09-15	Menschliches hcar-ähnliches protein und dafür kodierende nukleinsäure
ATE402954T1 (de)	2008-08-15	Menschliches a33-antigen-ähnliches protein und dafür kodierende nukleinsäure